European Psychiatry: Volume 15 -

European Psychiatry

Only show content I have access to (997)

Over 3 years (1069)

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save this undefined to your undefined account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your undefined account. Find out more about saving content to .

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
European Psychiatry
ISSN: 0924-9338

EISSN: 1778-3585

URL: /core/journals/european-psychiatry
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

European Psychiatry

Refine listing

Actions for selected content:

Volume 15 - October 2000

S28. Alzheimer𠀙s disease at the 3rd millennium - progress towards early diagnosis

Symposia

S28.03 Neuroimaging in Alzheimer's disease

S28. Alzheimer's disease at the 3rd millennium - progress towards early diagnosis

Symposia

S28.01 Changes in ABETA4 plasma levels and other markers: Results from a comprehensive multicenter study of peripheral bilogical and neuropsychological variables in early Alzheimer's disease

IS02. Initiating programmes on fighting stigma and discrimination because of schizophrenia (Supported by Eli Lilly)

Symposia

IS02.01 Fighting stigmatisation because of schizophrenia in spain: results

IS02.02 Fighting stigma and discrimination because of schizophrenia

IS02.03 Combining a programme against stigma with a comprehensive research programme on schizophrenia

IS02.04 The Austrian programme on fighting stigma because of schizophrenia

IS02.05 Anti-stigmatisation programme in Italy

IS02.06 Anti-stigmatisation programme in Greece

S29. Part II. Biomed collaborative studies in Europe: results and perspectives

Symposia

S29.01 Biomed-merope project for adults with psychiatric disorders and mental retardation

S29.02 A European technology for comparing mental health care systems. Adaptation, validation and application in a large sample of Italian catchment areas

S29.03 The family of the schizophrenic patient: Objective and subjective burden and coping strategies

S30. Behavioural pharmacology and MDMA (“Ecstasy”) - the importance of human subjects

Symposia

S30.02 Behavioural pharmacology of MDMA in nonhumans

S30.02 Effects of MDMA (ecstasy) on sensorimotor gating (prepulse inhibition) in humans after pretreatment with citalopram, haloperidol, or ketanserin

S30.04 Functional brain imaging after acute and chronic exposure to MDMA (“ecstasy”)

SES11. AEP Section “Psychotherapy”: Psychoanalysis and psychiatry: treating borderline patients

Symposia

SES11.02 Emerging from borderline state of mind: Psychoanalytic view

SES11.01 Causality of personality disorders and therapeutic intervention: A review of the psychoanalytic literature, 1908–1990

S30. Behavioural pharmacology and MDMA (“Ecstasy”) - the importance of human subjects

Symposia

S30.03 Subjective and reinforcing effects of MDMA and mCPP compared to d-amphetamine in humans

SES11. AEP Section “Psychotherapy”: Psychoanalysis and psychiatry: treating borderline patients

Symposia

SES11.03 Repairing the trauma: The internalization of the analytic relationship by the borderline patient

SES11.04 Psychotherapy of suicidal patients

SES11.05 Sojourn in the psyche: some effects of (borderline patients') projective identifications

European Psychiatry

Refine listing

Actions for selected content:

Save Search

Volume 15 - October 2000

S28. Alzheimer𠀙s disease at the 3rd millennium - progress towards early diagnosis

Symposia

S28. Alzheimer's disease at the 3rd millennium - progress towards early diagnosis

Symposia

IS02. Initiating programmes on fighting stigma and discrimination because of schizophrenia (Supported by Eli Lilly)

Symposia

S29. Part II. Biomed collaborative studies in Europe: results and perspectives

Symposia

S30. Behavioural pharmacology and MDMA (“Ecstasy”) - the importance of human subjects

Symposia

SES11. AEP Section “Psychotherapy”: Psychoanalysis and psychiatry: treating borderline patients

Symposia

S30. Behavioural pharmacology and MDMA (“Ecstasy”) - the importance of human subjects

Symposia

SES11. AEP Section “Psychotherapy”: Psychoanalysis and psychiatry: treating borderline patients

Symposia